SC Filed 2021-09-03 Event — SEC 0001193125-21-265615 →

Bain Capital Life Sciences Fund II, L.P. → Atea Pharmaceuticals, Inc. AVIR

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 20/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (10.7 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

10 filings by this filer

9 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 10.69

3,070,296 shares short · -61.1% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $228K

Point72 Asset Mgmt

Other 13D/G Filings on Atea Pharmaceuticals, Inc.

Filed	Form	Filer	Stake	Shares
2026-10-06	SCHEDULE 13G	TANG CAPITAL MANAGEMENT LLC	—	—	view →
2021-09-24	SC	Bain Capital Life Sciences Fund II, L.P.	—	—	view →

Other Filings by Bain Capital Life Sciences Fund II, L.P.

Filed	Form	Issuer	Stake	Shares
2026-01-08	SCHEDULE	Mersana Therapeutics, Inc.	—	—	view →
2024-04-12	SC	Savara Inc SVRA	—	—	view →
2023-07-19	SC	Savara Inc SVRA	—	—	view →
2022-04-14	SC	Mersana Therapeutics, Inc.	—	—	view →
2022-02-08	SC	Mersana Therapeutics, Inc.	—	—	view →
2022-01-03	SC	Mersana Therapeutics, Inc.	—	—	view →
2021-09-24	SC	Atea Pharmaceuticals, Inc. AVIR	—	—	view →
2021-03-17	SC	Savara Inc SVRA	—	—	view →
2021-01-12	SC	Mersana Therapeutics, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →